Fig. 2: Screening of airway cells with a FDA-approved or clinically active compound library for agents that reduce TMPRSS2-HiBiT levels. | Nature Communications

Fig. 2: Screening of airway cells with a FDA-approved or clinically active compound library for agents that reduce TMPRSS2-HiBiT levels.

From: A high-throughput screen for TMPRSS2 expression identifies FDA-approved compounds that can limit SARS-CoV-2 entry

Fig. 2

A Screening Assay workflow. Initial screening results yielded 100 compounds that decreased surface TMPRSS2 levels (by extracellular HiBiT detection) by 60%. From this, 24 compounds were selected for their clinical relevance and therapeutic potential and validated by IC50 assays. Of these, the most potent hits were halofuginone and homoharringtonine. B Scatterplot of hit compounds from both extracellular HiBiT and lytic HiBiT detection screens. Compounds that reduce membrane TMPRSS2-HiBiT signal (non-lytic extracellular HiBiT detection) are shown in pink, compounds that reduce total TMPRSS2-HiBiT signal (lytic HiBiT detection) are shown in purple. Some individual compounds are specified.

Back to article page